Address Nirmatrelvir/Ritonavir (Paxlovid) Interactions

July 2022

You can help answer questions when patients with COVID-19 taking nirmatrelvir/ritonavir (Paxlovid) present to the hospital.

It’s too soon to say if patients taking nirmatrelvir/ritonavir should continue it on admission. It’s okay to complete the course...but you’ll likely need to use a patient’s home supply.

Be ready to manage interactions...since the ritonavir component is a strong CYP3A4 and P-glycoprotein inhibitor.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote